WHO advisors urge China to release all data on COVID-19 origins
The WHO’s scientific advisors have called on China to release all data relating to the COVID-19 origins after a new report hinted at.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The WHO’s scientific advisors have called on China to release all data relating to the COVID-19 origins after a new report hinted at.
India's Glenmark Pharmaceuticals has got the final approval by the USFDA for its generic prochlorperazine maleate tablets, the generic version of compazine of.
The FDA’s advisory panel recommended full approval of Pfizer’s Covid antiviral treatment Paxlovid for high-risk adults.
The WHO slammed the Chinese authorities for not being transparent in sharing data related to COVID-19 origins and urged Beijing to conduct "investigations.
Lupin Digital Health, a fully-owned subsidiary of Lupin, stated 83.3% of study patients with the acute coronary syndrome (ACS) maintained their vital signs.
Jubilant HollisterStier, a subsidiary of India's Jubilant Pharmova, has got Canada's nod for a partially repayable loan of CAD 23.8 million ($17.7 million).
Sanofi, a French pharmaceutical major, announced it would slash the price of insulin, Lantus, by 78% for all U.S. patients with commercial insurance.
Glenmark Specialty SA, a subsidiary of India’s Glenmark Pharmaceuticals, has got investigational new drug clearance from the FDA to conduct clinical trials in.
Mediar Therapeutics gets $105 million financing from Novartis, Pfizer, Eli Lilly and Bristol Myers to advance portfolio of first-in-class fibrosis therapies.
India's Dr. Reddy's Laboratories has divested "certain" non-core dermatology brands of the company to Eris Lifesciences for INR 2.7 billion.